ABOUT
Patient-derived tumour xenografts (PDX) are now widely embraced by the scientific community as important preclinical tools for cancer biomarker discovery and drug development. However, they are costly and time-consuming to develop. As such, data sharing and collaboration has been essential to the growth of this research field but is still limited by a lack of central guidance and suitable infrastructures
The EurOPDX Consortium teamed up with other key academic and SME partners in a four-year project funded by the European Union’s Horizon 2020 research and innovation programme under the topic “Integrating Activities for Starting Communities”. The EDIReX project was built on the experience and successes of the Consortium, offering a cutting-edge, and much needed, EurOPDX Research Infrastructure for PDX research. The Research Infrastructure is currently part of the canSERV project (GA number 101058620).
